What is the official website of FUJIFILM Pharmaceuticals U.S.A., Inc. ?

The official website of FUJIFILM Pharmaceuticals U.S.A., Inc. is https://www.fujifilmpharma.com/?utm_source=LinkedIn&utm_medium=company_page&utm_campaign=visit_website.

What is FUJIFILM Pharmaceuticals U.S.A., Inc.'s cybersecurity risk score?

FUJIFILM Pharmaceuticals U.S.A., Inc. has an AI-generated cybersecurity risk score of 750 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has FUJIFILM Pharmaceuticals U.S.A., Inc. experienced?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has FUJIFILM Pharmaceuticals U.S.A., Inc. been affected by any supply chain cyber incidents ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have SOC 2 Type 1 certification ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. is not certified under SOC 2 Type 1.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have SOC 2 Type 2 certification ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. does not hold a SOC 2 Type 2 certification.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. comply with GDPR ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. is not listed as GDPR compliant.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have PCI DSS certification ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. does not currently maintain PCI DSS compliance.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. comply with HIPAA ?

According to Rankiteo, FUJIFILM Pharmaceuticals U.S.A., Inc. is not compliant with HIPAA regulations.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have ISO 27001 certification ?

According to Rankiteo,FUJIFILM Pharmaceuticals U.S.A., Inc. is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does FUJIFILM Pharmaceuticals U.S.A., Inc. operate in ?

FUJIFILM Pharmaceuticals U.S.A., Inc. operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does FUJIFILM Pharmaceuticals U.S.A., Inc. have ?

FUJIFILM Pharmaceuticals U.S.A., Inc. employs approximately 8 people worldwide.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. own any subsidiaries ?

FUJIFILM Pharmaceuticals U.S.A., Inc. presently has no subsidiaries across any sectors.

How many LinkedIn followers does FUJIFILM Pharmaceuticals U.S.A., Inc. have ?

FUJIFILM Pharmaceuticals U.S.A., Inc.'s official LinkedIn profile has approximately 1,355 followers.

What is the NAICS classification code for FUJIFILM Pharmaceuticals U.S.A., Inc. ?

FUJIFILM Pharmaceuticals U.S.A., Inc. is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have a Crunchbase profile ?

No, FUJIFILM Pharmaceuticals U.S.A., Inc. does not have a profile on Crunchbase.

Does FUJIFILM Pharmaceuticals U.S.A., Inc. have a LinkedIn profile ?

Yes, FUJIFILM Pharmaceuticals U.S.A., Inc. maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/fujifilm-pharma.

How many cybersecurity incidents has FUJIFILM Pharmaceuticals U.S.A., Inc. experienced ?

As of August 15, 2026, Rankiteo reports that FUJIFILM Pharmaceuticals U.S.A., Inc. has not experienced any cybersecurity incidents.

How many peer or competitor companies does FUJIFILM Pharmaceuticals U.S.A., Inc. have ?

FUJIFILM Pharmaceuticals U.S.A., Inc. has an estimated 5,727 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

FPUI

Boost Score +25 with badge (5 left)

750

/1000

Fair

775

/1000

Fair

FUJIFILM Pharmaceuticals U.S.A., Inc. Vendor Cyber Rating & Cyber Score

fujifilmpharma.com

Add Your Compliance Badge

About FUJIFILM Pharmaceuticals U.S.A., Inc. Our mission is to deliver innovative drugs to the broader population of patients worldwide at reasonable cost. FUJIFILM Pharmaceuticals U.S.A., Inc. started its operation in 2008 as FUJIFILM’s global center for new drug development. Today we are conducting multiple clinical trials in conjunction with medical institutions and industry partners that share the same vision of contributing to human health. Harnessed through FUJIFILM’s long-standing operations in photographic films, we are also providing DDS technologies to help achieve higher efficacy of treatments with less side effects. DDS technologies are expected to ensure the delivery of the therapeutic agent to the targeted area, while

FPUI A.I CyberSecurity Scoring

Scoring History

FPUI

FUJIFILM Pharmaceuticals U.S.A., Inc. CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

FPUI Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for FPUI

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for FUJIFILM Pharmaceuticals U.S.A., Inc. in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for FUJIFILM Pharmaceuticals U.S.A., Inc. in 2026.

Incident Types FPUI vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for FUJIFILM Pharmaceuticals U.S.A., Inc. in 2026.

Incident History - FPUI (X = Date, Y = Severity)

Loading…

SUBSIDIARY

FUJIFILM Pharmaceuticals U.S.A., Inc. Subsidiaries

Parent Company

FPUI

Pharmaceutical Manufacturing

Website: https://www.fujifilmpharma.com/?utm_source=LinkedIn&utm_medium=company_page&utm_campaign=visit_website

Company Size: 2-10 employees

No subsidiary data available for this company.

Loading…

FUJIFILM Pharmaceuticals U.S.A., Inc. Similar Companies

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Loading…

NEWS

FUJIFILM Pharmaceuticals U.S.A., Inc. CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

April 28, 2025 07:00 AM

Regeneron expands US manufacturing with $3B Fujifilm partnership

The company has started a supply partnership with Fujifilm Diosynth Biotechnologies valued at more than $3 billion.

Read Article

June 30, 2020 02:29 AM

Careers

Learn more about careers at Fujifilm, a globally recognized leader with more than 90 years of history in innovation and technology.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-74250

SUMMARY

In OpenStack Ironic before 38.0.1, the autodetect deploy interface may fail to run cleaning immediately after enrollment with, or changing to, the autodetect deploy interface.

Published

Date2026-08-14

Updated

Date2026-08-14

RISK INFORMATION (Score: 6.3)

cvss3

Base Score: 6.3

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:N/A:N

Impact Score

Exploitability

1.8

REFERENCES

https://bugs.launchpad.net/ossa/+bug/2163017

CVE-2026-74247

SUMMARY

A flaw was found in Red Hat Quay. A user with FEATURE_BUILD_SUPPORT enabled and repository write access can exploit a Server-Side Request Forgery (SSRF) vulnerability within the build API. This allows the user to provide a malicious URL, causing the Quay builder to make requests to internal network addresses. Such an action could lead to the disclosure of sensitive internal information.

Published

Date2026-08-14

Updated

Date2026-08-14

RISK INFORMATION (Score: 4.2)

cvss3

Base Score: 4.2

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

1.6

REFERENCES

CVE-2026-74245

SUMMARY

A flaw was found in Red Hat Quay's exported logs feature. An unauthenticated attacker with a valid file ID could download exported action logs without proper authorization. While file IDs are complex, they can be intercepted from plaintext email or webhook callbacks. This vulnerability leads to information disclosure, potentially exposing sensitive data such as usernames, email addresses, IP addresses, and action-specific metadata.

Published

Date2026-08-14

Updated

Date2026-08-14

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-74244

SUMMARY

A flaw was found in Red Hat Quay's Stripe billing webhook handler. This vulnerability allows an unauthenticated attacker to forge billing events by sending crafted JSON requests to the `/webhooks/stripe` endpoint without validating the Stripe-Signature header. Successful exploitation can lead to the unauthorized resetting of a namespace's build quota to its maximum and trigger unsolicited billing emails to namespace administrators.

Published

Date2026-08-14

Updated

Date2026-08-14

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-74243

SUMMARY

A flaw was found in Red Hat Quay. When the SECURITY_SCANNER_V4_PSK (pre-shared key) is not set, a remote unauthenticated attacker can send POST requests to the security scanner notification endpoint. This allows the attacker to flood the notification queue and inject path traversal characters into Clair API URL paths. The primary consequence is worker resource exhaustion and blind path manipulation on the configured Clair host, potentially leading to a denial of service.

Published

Date2026-08-14

Updated

Date2026-08-14

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L

Impact Score

2.5

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…